Retrospective Analysis of Third-Line and Fourth-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer
Retrospective Analysis of Third-Line and Fourth-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer
复制标题
DOI：
10.1016/j.cllc.2011.06.010
复制
发表时间：
2012-01-01
影响因子：
3.6
通讯作者：
Tamura, Tomohide
中科院分区：
文献类型：
--
作者：
Asahina, Hajime;Sekine, Ikuo;Tamura, Tomohide
The efficacy of third-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) remains unknown. The clinical outcome of 599 patients with advanced NSCLC who received first-line chemotherapy was evaluated. Thirty-eight percent of these patients could receive third-line chemotherapy, demonstrating the objective response rate of 17%. Randomized controlled trials of third-line treatment in patients with advanced NSCLC are warranted.Background: The efficacy of third-line and further-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) remains unknown. Patients and Methods: We evaluated the clinical outcome of third-and fourth-line chemotherapy for the treatment of advanced NSCLC in consecutive patients who received first-line chemotherapy at our institute between July 2002 and June 2006. From a hospital-based registry, the following data were extracted: (a) patient characteristics, (b) type of chemotherapeutic agents, and (c) objective response and survival data. Results: A total of 599 patients were included in this analysis. Overall, 69.3%, 38.4%, 17.7%, and 6.0% of the patients received second-, third-, fourth-, and fifth-line chemotherapy, respectively. Significant differences in age (P
